SENS Senseonics Holdings

Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference

Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference

GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2025 Healthcare Conference, being held in New York, NY.

2025 Stifel Healthcare Conference

Format: Fireside chat and one-on-one meetings

Date: Wednesday, November 12, 2025

Time: 4:40 pm ET

Webcast:

Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at .

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Senseonics Investor Contact

Jeremy Feffer

LifeSci Advisors





EN
10/11/2025

Underlying

SENSSenseonics Holdings

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Senseonics Holdings

 PRESS RELEASE
Free
SENS Senseonics Hold...

Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter ...

Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of $58-$62 million Expects to report fourth quarter and full year 2025 financial results on March 2, 2026 GERMANTOWN, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) s...

January 12, 2026 1 EN
 PRESS RELEASE
Free
SENS Senseonics Hold...

Senseonics Announces First Commercial Patients Using Eversense 365 Con...

Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM GERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable CGM systems for people with diabetes with Sequel MedTech, LLC, a company developing state-of-the-art insulin delivery technologies, have...

January 8, 2026 1 EN
 PRESS RELEASE
Free
SENS Senseonics Hold...

Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare...

Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2025 Healthcare Conference, being held in New York, NY. 2025 Stifel Healthcare Conference Format: Fireside chat and one-on-one meetingsDate: Wednesday, November 12, 2025Time: 4:40 pm...

November 10, 2025 1 EN
 PRESS RELEASE
Free
SENS Senseonics Hold...

Senseonics Announces Transfer to Nasdaq Stock Exchange

Senseonics Announces Transfer to Nasdaq Stock Exchange GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, has announced that as a decision in the best interest of the Company and its stockholders, it will transfer the listing of its common stock from the NYSE American to the Nasdaq Global Select Market (“Nasdaq”), effective after the market closes on November 14, 2025. The C...

November 10, 2025 1 EN
 PRESS RELEASE
Free
SENS Senseonics Hold...

Senseonics Holdings, Inc. Reports Third Quarter Financial Results

Senseonics Holdings, Inc. Reports Third Quarter Financial Results Generated Q3 revenue of $8.1 million, representing year-over-year growth of 90% Achieved a 160% increase in U.S. new patient starts over prior year Planning for the transition of CGM commercial responsibility from Ascensia Diabetes Care back to Senseonics GERMANTOWN, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, ...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch